TL;DR

Menopausal hormone therapy (MHT/HRT) is the most effective treatment for hot flashes, night sweats, and genitourinary symptoms. We typically use estradiol for symptoms and add progesterone or a progestin for endometrial protection if you have a uterus. Start near the time of menopause (when appropriate) for a more favorable risk–benefit profile. Testosterone can help a subset of postmenopausal women with diagnosed hypoactive sexual desire disorder (HSDD) when used in low, physiological doses and monitored. Our Solvion protocol individualizes route, dose, and follow-up to keep you safe and feeling like yourself.

Menopause & Perimenopause 101

Perimenopause is the transition leading up to menopause, often with irregular cycles and fluctuating hormones. Menopause is 12 months without a menstrual period. Common symptoms include hot flashes, night sweats, sleep disruption, mood changes, brain fog, vaginal dryness/pain, and lower sexual desire. Beyond symptoms, menopause can accelerate bone loss, shift body composition, and nudge cardiometabolic risk upward. Starting the right therapy near the time of menopause can improve comfort today and support long-term health.

First-Line: Estradiol for Symptom Relief

Systemic estradiol (patch, gel, spray, or oral) is the most effective treatment for vasomotor symptoms. Many women prefer transdermal routes for steady levels and favorable clot risk profiles; oral estradiol remains appropriate in selected cases. We tailor to your symptoms, medical history, preferences, and convenience. For women without a uterus (post-hysterectomy), estrogen alone is used; for women with a uterus, see the next section on endometrial protection.

Endometrial Safety: Progesterone/Progestin

If you have a uterus and use systemic estrogen, you also need progesterone or a progestin to protect the uterine lining. Many patients do well with micronized progesterone (often calming and sleep-friendly); others benefit from different progestins or a levonorgestrel IUD paired with systemic estradiol. We’ll decide between continuous (no scheduled bleeding) and cyclic (predictable light withdrawal bleed) regimens based on tolerance and goals.

Local (Vaginal) Estrogen & GSM Care

Genitourinary Syndrome of Menopause (GSM) includes vaginal dryness, pain with sex, recurrent UTIs, and urinary urgency. For GSM, low-dose vaginal estrogen (cream, tablet, ring) or vaginal DHEA can restore tissue health with minimal systemic absorption. Ospemifene (a selective estrogen receptor modulator) is another option. Local therapy can be used alone or alongside systemic therapy for best results.

When Testosterone Helps

Testosterone isn’t a general menopause tonic. The evidence-based indication in postmenopausal women is hypoactive sexual desire disorder (HSDD) after biopsychosocial evaluation. When appropriate, we use low-dose transdermal testosterone targeting physiological female ranges—avoiding supraphysiologic peaks. If there’s no clear benefit by ~6 months, we stop. We monitor for acne/oiliness, hair changes, lipids, and voice changes (rare at proper doses).

Benefits You Can Measure

• Vasomotor relief: hot flashes and night sweats improve in weeks.
• Sleep & mood: steadier sleep and daytime function; mood benefits are multifactorial and improve with exercise and stress care.
• Bone health: estradiol helps stabilize bone mineral density and lowers fracture trajectory over time.
• GSM: local therapy improves dryness, pain, lubrication, and urinary symptoms.
• Sexual health: in carefully selected women, testosterone can improve desire/arousal/satisfaction.
• Work & life performance: better sleep, symptom control, and GSM care can boost productivity and relationship quality.

Risks, Contraindications & Individualization

We avoid systemic hormone therapy in women with active breast cancer, unexplained vaginal bleeding, active or recent VTE, and severe liver disease, among others. Route matters: many women at higher clot risk favor transdermal estradiol. For breast health, risk varies with regimen/duration and personal history; we coordinate with your gynecologist/oncologist when needed. With testosterone, side effects are dose related and uncommon when kept in physiological ranges. As always, your plan is individualized and reviewed regularly.

Dosing Playbook (Illustrative, Not Prescriptive)

• Estradiol (systemic): start with a low–moderate transdermal patch/gel/spray; oral estradiol for select cases. Titrate to symptom control with safety in mind.
• Progesterone/progestin (uterus present): micronized progesterone nightly (continuous) or cyclic regimens; or a levonorgestrel IUD as the progestin component.
• Local estrogen for GSM: low-dose creams/tablets/rings (initially more frequent, then maintenance).
• Testosterone (HSDD only): low-dose transdermal with verified quality; monitor symptoms and labs; discontinue if no benefit by ~6 months.

Monitoring & Follow-Up: Solvion Protocol

Baseline: symptom inventory; BP/BMI/waist; breast history/status and screening; bleeding history; bone health baseline; relevant labs (lipids, A1c/glucose if indicated).

Recheck: at 6–12 weeks after start or dose change, then every 6–12 months once stable. We track: symptom scores, sleep, bleeding pattern, BP/weight, and labs as indicated. Bone density (DEXA) per risk profile.

Adjust/route switch: for side effects, BP/lipid shifts, bleeding changes, or inadequate symptom control. With testosterone, we add total/free T (assay-aware), skin/hair checks, and stop if no meaningful benefit.

Special Scenarios

• Perimenopause with irregular cycles: cyclic vs. continuous regimens based on bleeding tolerance and symptom targets.
• Early menopause (<45) or primary ovarian insufficiency (POI): strong case for systemic therapy usually until average menopause age, barring contraindications.
• Breast cancer survivorship: nonhormonal options first; local GSM strategies often feasible with oncology input.
• Obesity, diabetes, hypertension: favor transdermal routes; coordinate cardiometabolic care for best outcomes.

Lifestyle Stack That Multiplies Results

• Strength training + protein: preserve bone and lean mass.
• Sleep & stress: improve vasomotor triggers, mood, and appetite regulation.
• Cardio & mobility: heart health, energy, and joint comfort.
• Pelvic floor & sexual health counseling: targeted support for GSM-related pain and function.
• Weight & metabolic care: behavior-first; consider meds when appropriate and safe.

Cost, Access & Quality

Budget for consults, follow-ups, medications, and any imaging (e.g., DEXA). Some plans cover parts of therapy; others require cash pay. We use high-quality, verified products and explain pros/cons of compounding—especially relevant for testosterone where standardized female-dose products may be limited.

Results Timeline & Expectations

• Weeks 2–4: hot flashes/night sweats ease; sleep begins to steady.
• Months 2–3: mood, energy, and sexual function trending up; GSM improving with local therapy.
• Months 3–6: dose refinements; clearer changes in comfort and function.
• 6–12+ months: bone and cardiometabolic markers; long-term fine-tuning.

Why Solvion Health (Houston)

• Physician-led, evidence-based protocols; individualized route/dose.
• Timing matters: when appropriate, we aim to start near the menopause transition for a more favorable risk–benefit profile.
• Longevity lens: we track healthspan metrics (bone density, strength, gait/balance, sleep) alongside symptom relief.
• Clear follow-ups, coordination with oncology/cardiology/gynecology when needed.
• Transparent pricing; telehealth available.

Locations: Greater Houston • Telehealth options available

FAQs

Citations Summary (Plain-English Takeaways)

1. Menopause Society (NAMS) 2022 Hormone Therapy Position Statement: HT is the most effective therapy for vasomotor symptoms and GSM; individualize by age/timing/route; transdermal options have different risk profiles than oral.
2. Endocrine Society Clinical Practice Guideline: Evidence-graded recommendations for diagnosing menopause symptoms and using systemic vs. local therapies; shared decision-making emphasized.
3. ACOG guidance: Systemic estrogen is most effective for vasomotor symptoms; pair with progestin/progesterone if uterus present; use local estrogen for GSM.
4. Global Consensus on Testosterone Therapy for Women: Evidence supports testosterone for postmenopausal women with HSDD; avoid supraphysiologic dosing; monitor and discontinue if no benefit by ~6 months.
5. TIMING matters: Data support more favorable risk–benefit when HT is started within ~10 years of menopause or before age 60; route and dose individualization reduce risk.
6. Regulatory update (context): The FDA has announced removal of the long-standing boxed warning from many MHT products, reflecting updated evidence and timing/route nuances; labels still include specific warnings.